New triple therapy aims to shrink lung tumors before surgery
NCT ID NCT07318636
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new treatment for people with early-stage lung cancer that can be removed by surgery. The treatment combines NK cells (a type of immune cell), an immunotherapy drug (PD-1 antibody), and standard chemotherapy given before surgery. The main goals are to check safety and see how well the tumors respond. Only 10 participants will be enrolled.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, 510000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Lung cancer combo therapy aims to clear tumors before surgery
- New drug combo aims to shrink lung tumors before surgery
- Lung cancer drug combo trial pulled before it began
- New antibody combo aims to supercharge immune system against Hard-to-Treat cancers
- New drug cocktail aims to wipe out lung cancer before surgery
- Lung cancer trial tests cocktail of new drugs against standard care